ALSO NOTED: Altea garners $30M in venture money; Par loses patent fight; Ranbaxy JV unveils diabetes drug; and much more

> Altea Therapeutics raised more than $30 million in venture capital for development of pain management and diabetes patches. The Series C financing was led by Aperture Venture Partners, but includes Altea's Series B investors Domain, Venrock, and vSpring Capital. Release

> Par Pharmaceutical loses Zofran patent fight with GlaxoSmithKline. Release

> Ranbaxy's JV with Japan's Nippon Chemiphar unveils maiden diabetes drug. Story

> Human tissue supplier CryoLife agrees to pay $23 million to settle lawsuit over contamination. Report

> Biolex Therapeutics acquires LemnaGene, a French biotech startup researching protein development.  Release

> Boehringer Ingelheim wins regulatory nod for tipranavir, a non-peptidic protease inhibitor. Release

> Cortex launches Phase IIa studies of  Ampakine CX717 for ADHD and Alzheimer's Disease. Release

> Savient to set Phase III parameters with FDA on gout drug. Story

> British vaccine firm Acambis is starting trials of a vaccine to prevent infections from a new strain of clostridium difficile that has spawned outbreaks in at least 15 U.K. hospitals. Report

and finally...Sorry, herbal enthusiasts, researchers says Echinacea is a dud against colds. Article

Suggested Articles

Rachel Humphrey, M.D., who joined CytomX as chief medical officer after heading immuno-oncology at AstraZeneca and Eli Lilly, has made her exit.

Scientists have discovered a scorpion toxin could inspire treatments to block the inflammation that triggers chronic pain.

The phase 2 success keeps Hal Barron’s group on track to file for approval in multiple myeloma by the end of the year.